Veradermics, Incorporated (MANE) Stock Price
MANEStock
$97.93
Market Cap$4.09B
P/E—
PEG Ratio—
Div yield—
Beta-0.14
MANE Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)111.71%
Price vs S&P 500 (4W)-5.43%
VGM Score60.01
MANE Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.64 | -$0.58 | +9.56%(+$0.06) | |
| Q4 2025 | -$18.24 | -$104.54 | -473.14%(-$86.30) |
MANE Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.40
4.40
4.33
4.31
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MANEVeradermics, Incorporated | — | — | B | $97.93 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Veradermics, Incorporated
Veradermics Inc is a clinical-stage biopharmaceutical company developing therapeutics for aesthetic and dermatological conditions. The company addresses treatment gaps in high-prevalence skin disorders with novel therapeutic approaches.